Board of Directors

 

 

President

Mary Nteris

 Mary Nteris photo cropped

Dr Mary Nteris is Head of Regulatory Affairs, ANZ, for Pfizer Essential Healthcare. Prior to joining Pfizer, Mary had oversight of the ANZ regulatory activities at Hospira.   
 
Mary worked in acadaemia/research prior to entering the pharmaceutical industry.  She commenced her regulatory experience with a large, head-office biopharmaceutical organisation, leading teams and developing strategies for much of her time there. Subsequently, she led the provision of regulatory consulting services across Asia Pacific (excl Japan) for a clinical research organisation.
                                      
An active member of ARCS, Mary was elected to the Board of Directors in 2013, and has held the role of president since 2015.
 
Mary holds a PhD in pharmacology, is a graduate of the Australian Institute of Company of Directors.

 

Director

Alex Leung

Alex lowres

Alex is currently at LCN International and has over 20 years’ of experience in leadership roles in quality and regulatory affairs in Asia Pacific, Alex led a network of quality and regulatory professionals in Sydney, Tokyo, Beijing, Shanghai and Shenzhen, set long-term regulatory strategies to complement business growth in the region. In addition to the matured markets of Australia/New Zealand and Japan, Alex was also responsible for China and other emerging markets in Asia, including India, Taiwan, South Korea, Hong Kong, Singapore, Thailand, Indonesia, Philippines and Malaysia.

Alex holds a bachelor’s degree in engineering from Newcastle University, UK, master’s degree in engineering from Steven’s Institute of Technology, USA and MBA from Deakin University, Australia.

Director

Elizabeth Joshi

liz-pic

Regulatory affairs experience over 18 years working in Australia and NZ in pharmaceuticals and consumer care products involved in new product registrations, orphan designation, mergers, scheduling, and major consultative regulatory reform.

 

 Elizabeth holds a bachelor and masters in pharmacy.

 

Director

George Papadopoulos

George-119 A 2.8

George has more than 24 years’ experience in the pharmaceutical industry including clinical research, health economics, reimbursement, pricing and business development. He has worked in both the local operating company and global levels in increasing levels of responsibility. He has worked for leading pharmaceutical companies in Australia, Belgium and the United States including Pharmacia,Johnson & Johnson, Schering-Plough and Merck. George recently returned to Australia and established Emerald Corporate Group, a strategic consultancy George’s strengths are his ability to develop health economic and reimbursement strategic plans, strategic pricing initiatives, and the early commercial assessment of opportunities. George has put many of these strategies into practice around the world, including the successful reimbursement and timely market access for healthcare technologies, publication in peer reviewed journals and strategic stakeholder meetings. This is combined with his expertise and understanding of US, Canadian, European, Asia Pacific and Japanese market access issues developed through his vast global network of colleagues in government, academia and the healthcare industry.

 

Director

Jessica Keast

 J Keast photo

Jessica currently works a consultant providing strategic management expertise in prescription medicines and devices.


Director

Company Secretary

Kaylene O'Shea

Kaylene OShea smaller version

Kaylene has worked in the pharmaceutical industry for more than 25 years. During that time, Kaylene has been employed in six companies ranging from small biotechs to large multinationals. The roles she has held have encompassed all aspects of the medical function within those organisations.

Kaylene currently holds the role of Senior Director, Head of Clinical Operations, Asia Pacific for Celgene. This role encompasses the oversight of the clinical operations function within the Asia Pacific Region with personnel located in Australia, China, Taiwan and Korea. She assumed responsibility for this regional role in 2011. At the time of her appointment, clinical operations did not exist so her key focus then was to build out the function within the Asian region. The role requires the strategic and effective management of all clinical trials conducted in Australia, New Zealand, Taiwan, China, Korea, Hong Kong and Singapore across phases 1 to 4 of drug development.

ARCS Vice President and Director

Lucas Litewka

L Litewka small version

Lucas joined the University of the Sunshine Coast (USC), as the inaugural Director of the Clinical Trials Centre (CTC). The primary focus of this role was to take a greenfield opportunity and create an industry-focused Clinical Trials Centre on the Sunshine Coast. This bold initiative included negotiating cross-institutional partnerships with Chief Executive Officers from: Public Hospitals, Private University Hospital, and primary care networks to focus on major health issues affecting the community and the broader Sunshine Coast region.


Lucas has demonstrated his effectiveness as a member of a high performance leadership team in the formulation, development and implementation of critical business strategies both at Board level and within organisations on senior leadership teams. He has a sound understanding of the Hospital, Health, University and Research sectors, along with the ability to understand and interpret government policy to align with the organisation’s business strategy and the ability to build strong relationships across all levels in an ethical and sustainable manner.